80.61
Billiontoone Inc stock is traded at $80.61, with a volume of 557.47K.
It is down -2.63% in the last 24 hours and up +16.64% over the past month.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
See More
Previous Close:
$82.79
Open:
$84.53
24h Volume:
557.47K
Relative Volume:
1.87
Market Cap:
$3.71B
Revenue:
$305.11M
Net Income/Loss:
$-196.00K
P/E Ratio:
-12,401.54
EPS:
-0.0065
Net Cash Flow:
-
1W Performance:
-12.36%
1M Performance:
+16.64%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Billiontoone Inc Stock (BLLN) Company Profile
Name
Billiontoone Inc
Sector
Industry
Phone
650-460-2551
Address
1035 O'BRIEN DRIVE, MENLO PARK
Compare BLLN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BLLN
Billiontoone Inc
|
80.61 | 3.81B | 305.11M | -196.00K | 0 | -0.0065 |
|
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Billiontoone Inc Stock (BLLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Initiated | Guggenheim | Buy |
| Dec-01-25 | Initiated | BTIG Research | Buy |
| Dec-01-25 | Initiated | JP Morgan | Overweight |
| Dec-01-25 | Initiated | Jefferies | Hold |
| Dec-01-25 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Initiated | Stifel | Buy |
| Dec-01-25 | Initiated | Wells Fargo | Equal Weight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Billiontoone Inc Stock (BLLN) Latest News
BillionToOne to Report Q1 2026 Earnings on May 6 - National Today
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewswire
Top Billiontoone (BLLN) Competitors 2026 - MarketBeat
BLLN Options Volatility — NASDAQ:BLLN - TradingView — Track All Markets
BLLN Options Chain — NASDAQ:BLLN - TradingView — Track All Markets
J.P. Morgan Maintains BillionToOne(BLLN.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Why BillionToOne Shares Keep Sliding Despite Strong Results - TipRanks
BLLN Technical Analysis | Trend, Signals & Chart Patterns | BILLIONTOONE INC CL A (NASDAQ:BLLN) - ChartMill
BillionToOne Inc (BLLN) Shares Gap Down to $84.655 on Apr 9 - GuruFocus
Why BillionToOne’s Hot Rally Is Suddenly Cracking - TipRanks
MacKenzie Scott Has Now Given Over $1 Billion to 1 Area of Higher Education - inc.com
Highlighting BillionToOne And 2 Other Stocks That Investors May Be Undervaluing - Sahm
Why BillionToOne, Inc. Class A Shares Are Surging - TipRanks
Why BillionToOne Stock Is Suddenly Surging Higher - TipRanks
BillionToOne, Inc. (BLLN) Options Chain - Yahoo! Finance Canada
BillionToOne appoints Allen Chen as oncology VP By Investing.com - Investing.com Canada
BillionToOne Q4 2025 slides: profitability achieved amid 113% revenue surge - Investing.com
BillionToOne Appoints Dr. Allen Chen as Vice President of Medica - GuruFocus
BillionToOne appoints Allen Chen as oncology VP - Investing.com
Billiontoone appoints Dr. Allen Chen as vice president of medical affairs and clinical development, oncology - marketscreener.com
Billiontoone Appoints Dr. Allen Chen As Vice President Of Medical Affairs And Clinical Development, Oncology - TradingView — Track All Markets
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology - Bitget
Guggenheim Maintains BillionToOne(BLLN.US) With Buy Rating, Cuts Target Price to $100 - Moomoo
InvestingPro spotted BillionToOne’s 46% drop four months in advance By Investing.com - Investing.com Australia
Why BillionToOne, Inc. Class A Shares Are Sinking - TipRanks
BillionToOne And 2 More Growth Companies With Strong Insider Ownership - Yahoo Finance
BillionToOne Inc (BLLN) Shares Up 3.33% on Mar 25 - GuruFocus
BillionToOne, Inc.(NasdaqGS: BLLN) added to S&P Global BMI Index - MarketScreener
Piper Sandler reiterates BillionToOne stock rating on NIPT tech By Investing.com - Investing.com Nigeria
Piper Sandler reiterates BillionToOne stock rating on NIPT tech - Investing.com
Billiontoone (BLLN) Stock Trends and Sentiment 2026 $BLLN - MarketBeat
BillionToOne Inc (BLLN) Stock Price Up 3.48% on Mar 16 - GuruFocus
Billiontoone (BLLN) Stock Forecast and Price Target 2026 $BLLN - MarketBeat
BillionToOne (NASDAQ: BLLN) Shares Climb 8% Amid Strong Momentum in Precision Diagnostics Sector - International Business Times Australia
BTIG lowers BillionToOne stock price target on valuation multiples - Investing.com Nigeria
BillionToOne, Inc.: Fundamental Analysis and Financial Ratings | BLLN | US0901681058 - marketscreener.com
BillionToOne Inc (BLLN) Shares Up 6.14% on Mar 13 - GuruFocus
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148 - Minichart
BillionToOne 10-K: Revenue $305.1M, EPS $0.14 - TradingView
Billiontoone (NASDAQ:BLLN) Hits New 1-Year LowHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BillionToOne Medicare Win Puts North Star Economics In Focus - Yahoo Finance
Billiontoone Inc Stock (BLLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):